» Articles » PMID: 3476310

Human Chronic Myeloid Leukemic Cell Line with Positive Philadelphia Chromosome Exhibits Megakaryocytic and Erythroid Characteristics

Overview
Journal Exp Hematol
Specialty Hematology
Date 1987 Sep 1
PMID 3476310
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

A cell line (LAMA-84) has been established from the blood of a patient with chronic myeloid leukemia in acute phase. LAMA-84 cells retained the patient's chromosome abnormalities, i.e., triplication of all chromosomes except chromosome 18, the presence of Philadelphia (Ph) chromosome in 4-5 copies, and the presence of chromosome markers. LAMA-84 cells have morphological features of undifferentiated blast cells, but analyses have indicated that they belong to the megakaryocytic lineage; platelet peroxidase (PPO) was found in 8.5% of cells; LAMA-84 cells reacted spontaneously with poly- and monoclonal antibodies against the platelet glycoproteins (GP) IIb, IIIa, and the GPIIb/IIIa complex, whose presence was confirmed by crossed immunoelectrophoresis. LAMA-84 cells lack the membrane characteristics of lymphoid and mature granulocytic cells but do, however, react with certain antibodies to immature myeloid cells. Furthermore, they are positive with an antiglycophorin antibody, and contain alpha- and gamma-globin mRNA, thus demonstrating erythroid marker expression. Thus LAMA-84 is a tripotent, megakaryocytic, erythroid, and granulocytic cell line. The megakaryocytic and erythroid markers were enhanced by the addition of DMSO, butyrate, TPA, and hemin. The LAMA-84 cell line represents an interesting tool for the study of megakaryocytic and erythroid differentiation and the mechanisms of neoplastic growth.

Citing Articles

Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia.

Alves R, Goncalves A, Jorge J, Almeida A, Sarmento-Ribeiro A Biomedicines. 2022; 10(5).

PMID: 35625893 PMC: 9138473. DOI: 10.3390/biomedicines10051158.


In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features.

Tusa I, Cheloni G, Poteti M, Silvano A, Tubita A, Lombardi Z Target Oncol. 2020; 15(5):659-671.

PMID: 32780298 PMC: 7568716. DOI: 10.1007/s11523-020-00741-x.


CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of invasion.

Kanjee U, Gruring C, Chaand M, Lin K, Egan E, Manzo J Proc Natl Acad Sci U S A. 2017; 114(44):E9356-E9365.

PMID: 29078358 PMC: 5676921. DOI: 10.1073/pnas.1711310114.


Snail transcription factors in hematopoietic cell development: a model of functional redundancy.

Pioli P, Weis J Exp Hematol. 2014; 42(6):425-30.

PMID: 24674754 PMC: 4071116. DOI: 10.1016/j.exphem.2014.03.002.


Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

Nies A, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M Clin Cancer Res. 2013; 20(4):985-94.

PMID: 24352644 PMC: 3932302. DOI: 10.1158/1078-0432.CCR-13-1999.